Consolidated Statements of Changes in Equity - USD ($) $ in Thousands		Total		IPO	Conversion Of Convertible Common Units	Common Units		Common Units Conversion Of Convertible Common Units		Common Stock	Common Stock IPO	Common Stock Conversion Of Convertible Common Units	Additional Paid in Capital	Additional Paid in Capital IPO	Additional Paid in Capital Conversion Of Convertible Common Units	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interests	Noncontrolling Interests Conversion Of Convertible Common Units
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2022		$ 10,796
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(3,494)
Redeemable noncontrolling interests, ending balance at Dec. 31, 2023		7,302
Balance, beginning of period (in shares) at Dec. 31, 2022						482,726,544	[1]			0
Balance, beginning of period at Dec. 31, 2022		1,039,510				$ 510,968				$ 0			$ 0			$ 26,533	$ 101,549	$ 400,460
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health, Inc.		53,904															53,904
Net income attributable to noncontrolling interests		78,567																78,567
Other comprehensive income (loss)		(7,972)														(7,972)
Distributions to noncontrolling interests		(63,875)																(63,875)
Redemption of equity attributable to noncontrolling interests		(26,024)				$ (14,990)												(11,034)
Vesting of class C units (in shares)	[1]					2,196,284
Vesting of Class C Units		904				$ 904
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs (in shares)	[1]					2,196,284
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs		904				$ 904
Balance, ending of period (in shares) at Dec. 31, 2023						484,922,828	[1]			0
Balance, ending of period at Dec. 31, 2023		1,075,014				$ 496,882				$ 0			0			18,561	155,453	404,118
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(6,144)
Redeemable noncontrolling interests, ending balance at Dec. 31, 2024	[2]	1,158
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health, Inc.		210,343															210,343
Net income attributable to noncontrolling interests		95,509																95,509
Other comprehensive income (loss)		(8,824)														(8,824)
Distributions to noncontrolling interests		(72,856)																(72,856)
Vesting of class C units (in shares)						986,855	[1]				13,800,000
Vesting of Class C Units		738		$ 198,792		$ 738					$ 138			$ 198,654
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs (in shares)						986,855	[1]				13,800,000
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs		738		$ 198,792		$ 738					$ 138			$ 198,654
Conversion of member units to common stock (shares)								(485,909,683)	[1]			128,963,328
Stock Issued During Period, Value, Conversion of Convertible Securities					$ 0			$ (497,620)				$ 1,290			$ 536,291				$ (39,961)
Proceeds from the sale of noncontrolling interest		5,364											2,351					3,013
Vesting of restricted stock unit awards (in shares)										32,227
Tax withholding on vesting of restricted stock unit awards (in shares)										(8,200)
Tax withholding on vesting of restricted stock unit awards		(121)											(121)
Forfeiture of restricted stock awards (in shares)										(39,537)
Equity-based compensation		$ 17,240											17,240
Balance, ending of period (in shares) at Dec. 31, 2024		142,747,818				0	[1]			142,747,818
Balance, ending of period at Dec. 31, 2024		$ 1,521,199	[2]			$ 0				$ 1,428			754,415			9,737	365,796	389,823
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(2,408)
Redeemable noncontrolling interests, ending balance at Dec. 31, 2025	[2]	(1,250)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health, Inc.		135,811															135,811
Net income attributable to noncontrolling interests		96,732																96,732
Other comprehensive income (loss)		(13,347)														(13,347)
Distributions to noncontrolling interests		$ (88,239)																(88,239)
Vesting of class C units (in shares)		7,553
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs (in shares)		7,553
Vesting of restricted stock unit awards (in shares)										659,466
Vesting of restricted stock unit awards		$ 5								$ 5			0
Tax withholding on vesting of restricted stock unit awards (in shares)										(153,264)
Tax withholding on vesting of restricted stock unit awards		(2,087)											(2,087)
Forfeiture of restricted stock awards (in shares)										(46,390)
Repurchase of common stock (in shares)										(351,012)
Repurchase of common stock, net of taxes		(3,153)								$ (4)			(3,149)
Equity-based compensation		$ 39,293											39,293
Balance, ending of period (in shares) at Dec. 31, 2025		142,864,171				0	[1]			142,864,171
Balance, ending of period at Dec. 31, 2025		$ 1,686,214	[2]			$ 0				$ 1,429			$ 788,472			$ (3,610)	$ 501,607	$ 398,316

[1] (*) See Note 1, Description of the Business and Basis of Presentation - Initial Public Offering and Corporate Conversion, for further discussion.

[2] As of December 31, 2025 and 2024, the consolidated balance sheets included total liabilities of consolidated variable interest entities of $335.1 million and $306.4 million, respectively. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion.